… and safety in comparison with reference drug. The aim of this … The anti-TNF-α reference
drugs available to treat IBD … Similarity needs to be proven in terms of their characteristics, …

… article, we present a comprehensive review of the available literature regarding the efficacy
of IMM in the prevention and suppression of ADA development to anti-TNF … biosimilars share …

… of anti-TNF in symptomatic patients with high anti-drug antibody levels. Despite therapeutic
trough levels and no anti-drug … , 9% of respondents would increase the drug dose or add a …

… biosimilars is mandatory since May 2014 for all anti-TNF naive patients and those on drug
… Moreover, the development of a biosimilar with improved characteristics such as a more …

… findings described in this review is that anti-TNF agents were … With approval and overspread
use of anti-TNF biosimilars, it … difficulties in access to the drug in the private and public …

… drug at a particular ‘disease moment' and this dosage regimen is determined by drug
characteristics, patient (baseline) characteristics and the … For the anti-TNF biologicals, primary non-…

… and small intestine, 5-ASA must be bound to a drug-delivery … systemic side effects, as they
only act locally on the intestinal … A subcutaneous formulation of the IFX biosimilars, CT-P13 (…

… -drug antibodies, is of major concern in the use of anti-TNF … Recently, a subcutaneous
formulation of the biosimilar CT-P13 (IFX… patient characteristics (body weight, gender) and disease …

… Provides guidance regarding practical aspects of patient … originator drug are unlikely to benefit
from a trial of a biosimilar and … Six anti-TNF biosimilars have been approved in the US, but …

… The biosimilar product is highly similar to its originator biological drug infliximab and is
therefore … In this review, several aspects of potential targets for anti-TNF antibodies have been …